Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 39, Issue 3, 2004, Pages 277-288

  Stokvis, E ^a   Rosing, H ^a   Crul, M ^a   Rieser, M J ^b   Heck, A J R ^c   Schellens, J H M ^a,d   Beijnen, J H ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ABT 518; Anticancer drug; Bioanalysis; Liquid chromatography tandem mass spectrometry; Matrix metalloproteinase inhibitor

Indexed keywords

BODY FLUIDS; CHEMICAL ANALYSIS; ENZYMES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; TUMORS;

ANTICANCER DRUGS; AQUEOUS PHASE;

DRUG PRODUCTS;

ABT 518; AMMONIUM DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; DRUG METABOLIZING ENZYME; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METHANOL; UNCLASSIFIED DRUG;

ALKALINITY; AQUEOUS SOLUTION; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METASTASIS; PARTICLE SIZE; PH MEASUREMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOLID PHASE EXTRACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; VALIDATION PROCESS;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FORMAMIDES; HUMANS; METALLOPROTEASES; NEOPLASMS; PLASMA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 1642350893     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.579     Document Type: Article

References (17)

1. Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992; 14: 455.
2. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs 1997; 15: 175.
3. Liotta LA, Steltler-Stevenson WG. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1990; 1: 99.
4. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA 2000; 97: 3884.
5. Albert DH, Morgan DW, Magoc T, Tapang P, Kherzai A, Marcotte P, Elsmore I, Glaser K, Pease L, Li J, Leal J, Michaelides M, Curtin M, Holms J, Wada C, Dai Y, Davidson SK. Preclinical pharmacology of ABT-518, a novel and potent inhibitor of gelatinase A and B with anti-tumor activity. Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Clin. Cancer Res. 2000; 6: (Suppl.): 301.
6. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Avanzato Chiodo T, Hawkins MJ. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 1998; 16: 2150.
7. Wada CK, Holms JH, Curtin ML, Dai Y, Florjanic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxmates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 2002; 45: 219.
8. Mück W. Quantitative analysis of pharmacokinetic study samples by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Pharmazie 1999; 54: 639.
9. Watt AP, Morrisoon D, Locker KL, Evans DC. Higher throughput bioanalysis by automation of a protein precipitation assay using a 96-well format with detection by LC-MSMS. Anal. Chem. 2000; 72: 979.
10. Wu JT, Zeng H, Qian MX, Brogdon BL, Unger SE. Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. Anal. Chem. 2000; 72: 62.
11. Ramos L, Bakhtiar R, Tse FLS. Liquid-liquid extraction using 96-well plate format in conjunction with liquid chromatography/tandem mass spectrometry for quantitative determination of methylphenidate (Ritalin®) in human plasma. Rapid Commun. Mass Spectrom. 2000; 14: 740.
12. U.S. Food and Drug Administration: Center for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. www.fda.gov/cder/guidance/4252fnl.htm, 2001.
13. Chernushevich IV, Ens W, Standing KG. Electrospray ionization time-of-flight mass spectrometry. In Electrospray Ionization Mass Spectrometry: Fundamentals Instrumentation and Applications, Cole RB (ed). Wiley: New York, 1997; 230.
14. McMurry J. Organic Chemistry. Wadsworth: Belmont, CA, 1992; 964.
15. Lemoine J, Fournet B, Despeyroux D, Jennings KR, Rosenberg R, De Hoffmann E. Collision-induced dissociation of alkali metal cationized and permethylated oligosaccharides: Influence of the collision energy and the collision gas for the assignment of linkage position. J. Am. Soc. Mass Spectrom. 1993; 4: 197.
16. Zhou S, Cook KD. Protonation in electrospray mass spectrometry: Wrong-way-round or right-way-round? J. Am. Soc. Mass Spectrom. 2000; 11: 961.
17. Sancho JV, Pozo OJ, López FJ, Hernández F. Different quantitation approaches for xenobiotics in human urine samples by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2002; 16: 639.